GSK: revises agreement with Zhifei for Shingrix in China

(CercleFinance.com) - GSK announces that it has reached an agreement with Chongqing Zhifei Biological Products (Zhifei) to revise the sales terms under which Zhifei will be able to sell Shingrix, GSK's shingles vaccine, in mainland China.


The revised agreement extends the initial 3-year period (2024-2026), during which Zhifei holds exclusive rights to import, distribute and co-promote the vaccine in mainland China, by a further 8 years to 2034.

The parties anticipate that Zhifei will purchase volumes of Shingrix with a potential total value to GSK of £2.3bn (at current exchange rates) over the 6-year period 2024-2029. Previously contracted minimum purchase levels no longer apply.

In addition, Zhifei is committed to working exclusively with GSK to explore a potential collaboration, for an initial term of 10 years, for the commercialization of a respiratory syncytial virus (RSV) vaccine in mainland China, subject to regulatory approval of the vaccine.


Copyright (c) 2024 CercleFinance.com. All rights reserved.